232 related articles for article (PubMed ID: 27577794)
1. Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.
Okada T; Lee AY; Qin LX; Agaram N; Mimae T; Shen Y; O'Connor R; López-Lago MA; Craig A; Miller ML; Agius P; Molinelli E; Socci ND; Crago AM; Shima F; Sander C; Singer S
Cancer Discov; 2016 Oct; 6(10):1148-1165. PubMed ID: 27577794
[TBL] [Abstract][Full Text] [Related]
2. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
3. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.
Lee SL; Chou CC; Chuang HC; Hsu EC; Chiu PC; Kulp SK; Byrd JC; Chen CS
PLoS One; 2013; 8(6):e67149. PubMed ID: 23840605
[TBL] [Abstract][Full Text] [Related]
4. Receptor-specific mechanisms regulate phosphorylation of AKT at Ser473: role of RICTOR in β1 integrin-mediated cell survival.
Riaz A; Zeller KS; Johansson S
PLoS One; 2012; 7(2):e32081. PubMed ID: 22384145
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin and Rictor control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton.
He Y; Li D; Cook SL; Yoon MS; Kapoor A; Rao CV; Kenis PJ; Chen J; Wang F
Mol Biol Cell; 2013 Nov; 24(21):3369-80. PubMed ID: 24006489
[TBL] [Abstract][Full Text] [Related]
6. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics.
Li CF; Wang JM; Kang HY; Huang CK; Wang JW; Fang FM; Wang YH; Wu WR; Li SH; Yu SC; Lee JC; Lan J; Shiue YL; Wu LC; Huang HY
Clin Cancer Res; 2012 Mar; 18(6):1598-610. PubMed ID: 22322669
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
8. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
[TBL] [Abstract][Full Text] [Related]
9. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.
Boulbes D; Chen CH; Shaikenov T; Agarwal NK; Peterson TR; Addona TA; Keshishian H; Carr SA; Magnuson MA; Sabatini DM; Sarbassov dos D
Mol Cancer Res; 2010 Jun; 8(6):896-906. PubMed ID: 20501647
[TBL] [Abstract][Full Text] [Related]
10. Rictor regulates cell migration by suppressing RhoGDI2.
Agarwal NK; Chen CH; Cho H; Boulbès DR; Spooner E; Sarbassov DD
Oncogene; 2013 May; 32(20):2521-6. PubMed ID: 22777355
[TBL] [Abstract][Full Text] [Related]
11. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
[TBL] [Abstract][Full Text] [Related]
12. The PTEN-AKT-mTOR/RICTOR Pathway in Nasal Natural Killer Cell Lymphoma Is Activated by miR-494-3p via PTEN But Inhibited by miR-142-3p via RICTOR.
Chen HH; Huang WT; Yang LW; Lin CW
Am J Pathol; 2015 May; 185(5):1487-99. PubMed ID: 25907832
[TBL] [Abstract][Full Text] [Related]
13. Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific domains.
Wang JQ; Chen JH; Chen YC; Chen MY; Hsieh CY; Teng SC; Wu KJ
PLoS One; 2013; 8(6):e65586. PubMed ID: 23762398
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.
Gulhati P; Cai Q; Li J; Liu J; Rychahou PG; Qiu S; Lee EY; Silva SR; Bowen KA; Gao T; Evers BM
Clin Cancer Res; 2009 Dec; 15(23):7207-16. PubMed ID: 19934294
[TBL] [Abstract][Full Text] [Related]
15. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
16. Identification of rictor as a novel substrate of Polo-like kinase 1.
Shao T; Liu X
Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
[TBL] [Abstract][Full Text] [Related]
17. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.
Kim EK; Yun SJ; Ha JM; Kim YW; Jin IH; Yun J; Shin HK; Song SH; Kim JH; Lee JS; Kim CD; Bae SS
Oncogene; 2011 Jun; 30(26):2954-63. PubMed ID: 21339740
[TBL] [Abstract][Full Text] [Related]
18. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
[TBL] [Abstract][Full Text] [Related]
19. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
[TBL] [Abstract][Full Text] [Related]
20. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
